207 related articles for article (PubMed ID: 21490101)
1. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.
Funaoka Y; Sakamoto N; Suda G; Itsui Y; Nakagawa M; Kakinuma S; Watanabe T; Mishima K; Ueyama M; Onozuka I; Nitta S; Kitazume A; Kiyohashi K; Murakawa M; Azuma S; Tsuchiya K; Watanabe M
J Virol; 2011 Jun; 85(12):5986-94. PubMed ID: 21490101
[TBL] [Abstract][Full Text] [Related]
2. Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress.
Chida T; Watanabe S; Ohta K; Noritake H; Ito M; Suzuki T; Suda T; Kawata K
Free Radic Biol Med; 2024 Feb; 212():199-206. PubMed ID: 38103659
[TBL] [Abstract][Full Text] [Related]
3. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
[TBL] [Abstract][Full Text] [Related]
4. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro.
Ikeda F; Dansako H; Nishimura G; Mori K; Kawai Y; Ariumi Y; Miyake Y; Takaki A; Nouso K; Iwasaki Y; Ikeda M; Kato N; Yamamoto K
Liver Int; 2010 Oct; 30(9):1324-31. PubMed ID: 20602680
[TBL] [Abstract][Full Text] [Related]
5. Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV.
Campos LB; de Almeida NAA; de Santana CG; Barbosa ENP; Horta MAP; Amendola Pires M; Brandão Mello CE; de Paula VS; de Barros JJF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680226
[TBL] [Abstract][Full Text] [Related]
6. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
7. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
[TBL] [Abstract][Full Text] [Related]
8. SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.
Poat B; Hazari S; Chandra PK; Gunduz F; Balart LA; Alvarez X; Dash S
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20949125
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus.
Zhao LJ; He SF; Wang W; Ren H; Qi ZT
Cytokine; 2016 Apr; 80():48-55. PubMed ID: 26945996
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context.
Kichatova VS; Kyuregyan KK; Soboleva NV; Karlsen AA; Isaeva OV; Isaguliants MG; Mikhailov MI
J Immunol Res; 2018; 2018():7685371. PubMed ID: 29577052
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1.
He CL; Liu M; Tan ZX; Hu YJ; Zhang QY; Kuang XM; Kong WL; Mao Q
World J Gastroenterol; 2018 Jan; 24(2):226-236. PubMed ID: 29375208
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
[TBL] [Abstract][Full Text] [Related]
14. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
[TBL] [Abstract][Full Text] [Related]
15. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
Hu Z; Liu Y; Qiu L; Fan Z; Nie W; Liang S; Jin R
Virol J; 2015 Dec; 12():220. PubMed ID: 26684004
[TBL] [Abstract][Full Text] [Related]
16. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.
Hiraga N; Abe H; Imamura M; Tsuge M; Takahashi S; Hayes CN; Ochi H; Tateno C; Yoshizato K; Nakamura Y; Kamatani N; Chayama K
Hepatology; 2011 Sep; 54(3):764-71. PubMed ID: 21618576
[TBL] [Abstract][Full Text] [Related]
17. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
18. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance.
Zhu H; Nelson DR; Crawford JM; Liu C
J Interferon Cytokine Res; 2005 Sep; 25(9):528-39. PubMed ID: 16181053
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.
Watanabe T; Sakamoto N; Nakagawa M; Kakinuma S; Itsui Y; Nishimura-Sakurai Y; Ueyama M; Funaoka Y; Kitazume A; Nitta S; Kiyohashi K; Murakawa M; Azuma S; Tsuchiya K; Oooka S; Watanabe M
Antimicrob Agents Chemother; 2011 Jun; 55(6):2537-45. PubMed ID: 21444704
[TBL] [Abstract][Full Text] [Related]
20. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
Erickson AK; Seiwert S; Gale M
Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
